- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07676032
Body Composition and Setup Errors in Radiotherapy (BODY-SET)
23 juin 2026 mis à jour par: Chaoxing Liu, Shijiazhuang People's Hospital
The Impact of Body Composition on Setup Errors in Patients Undergoing Radiotherapy With Thermoplastic Mask Immobilization: A Single-Center Prospective Cohort Study
This single-center prospective cohort study investigates the association between body composition parameters and setup errors in 120-150 patients receiving radiotherapy with thermoplastic mask immobilization.
Body composition (skeletal muscle mass, body fat percentage, phase angle, fat-free mass) will be measured using bioelectrical impedance analysis at baseline and at fraction 20.
Setup errors (six degrees of freedom) will be recorded via daily cone-beam computed tomography.
The primary outcome is the association between baseline body composition and setup errors.
Secondary outcomes include the relationship between body composition changes during radiotherapy and setup error evolution, and identification of threshold values for clinically significant setup error increases.
This study will provide evidence on whether body composition-beyond BMI-predicts radiotherapy setup accuracy, potentially enabling personalized immobilization and image-guided strategies.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Description détaillée
Radiotherapy is a cornerstone of cancer treatment, with approximately 50-70% of patients requiring radiotherapy during their disease course.
Accurate patient positioning is essential for ensuring adequate target volume coverage while sparing organs at risk.
Thermoplastic masks are among the most commonly used immobilization devices; however, setup reproducibility varies considerably among patients.
Previous studies have demonstrated that patients with BMI ≥24 kg/m² exhibit significantly greater setup errors across multiple directions in breast, cervical, and thoracic cancers compared with normal-weight patients.
However, BMI is a crude anthropometric measure that cannot distinguish between fat and muscle mass-two tissue types with fundamentally different mechanical properties that may affect mask fit and positional reproducibility.
Bioelectrical impedance analysis (BIA) provides a non-invasive, convenient method for measuring body composition parameters, including skeletal muscle mass (SMM), body fat percentage (BFP), phase angle (PhA), and fat-free mass (FFM).
Phase angle, in particular, reflects cell membrane integrity and cellular mass, and has been validated as a sensitive marker of muscle quality and nutritional status in cancer patients.
However, the value of BIA-derived body composition parameters in predicting radiotherapy setup errors has not been systematically explored.
This study is a single-center, prospective observational cohort study conducted at the Department of Radiation Oncology, Shijiazhuang People's Hospital, China.
A total of 120-150 patients with pathologically confirmed malignancies receiving radical or adjuvant intensity-modulated radiotherapy (≥25 fractions) with thermoplastic mask immobilization will be enrolled.
Body composition parameters will be measured using BIA at baseline (T0) and at fraction 20 (T1).
Setup errors (six degrees of freedom: Tx, Ty, Tz, Rx, Ry, Rz) will be recorded via cone-beam computed tomography (week 1: 3 times; thereafter: weekly).
The primary outcome is the association between baseline body composition parameters and setup errors.
Secondary outcomes include the relationship between body composition changes and setup error evolution, and identification of threshold values for clinically significant setup error increases.
Data will be analyzed using multiple linear regression and generalized estimating equations.
Results will be disseminated through peer-reviewed publications and conference presentations.
Type d'étude
Observationnel
Inscription (Estimé)
150
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Chaoxing Liu, Dr
- Numéro de téléphone: 86 17603119780
- E-mail: 15130068099@163.com
Sauvegarde des contacts de l'étude
- Nom: Xiaoyan Wang, Dr
- Numéro de téléphone: 86 15031163260
- E-mail: 15031163260@163.com
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
Méthode d'échantillonnage
Échantillon de probabilité
Population étudiée
Patients with pathologically confirmed malignancies receiving radical or adjuvant intensity-modulated radiotherapy at Shijiazhuang People's Hospital.
La description
Inclusion Criteria:
- Pathologically confirmed malignancy
- Age ≥18 years
- Receiving radical or adjuvant intensity-modulated radiotherapy (IMRT) with planned ≥25 fractions
- Immobilized with thermoplastic mask
- ECOG Performance Status 0-2
- Willing and able to provide written informed consent
Exclusion Criteria:
- Metal implants (pacemaker, artificial joints) affecting bioelectrical impedance analysis (BIA) measurements
- Severe edema or ascites
- Inability to cooperate with immobilization or CBCT scanning
- Radiotherapy interruption >5 fractions
- Pregnancy or lactation
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
|---|
|
High Muscle Mass Group
Patients with skeletal muscle mass above the sex-specific median
|
|
Low Muscle Mass Group
Patients with skeletal muscle mass below the sex-specific median
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
setup errors
Délai: Through study completion, an average of 6 months.
|
Six-degree-of-freedom setup errors (Tx, Ty, Tz, Rx, Ry, Rz) measured by cone-beam computed tomography (CBCT).
|
Through study completion, an average of 6 months.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Skeletal Muscle Mass
Délai: Baseline and fraction 20 (approximately 4 weeks after baseline)
|
Change in skeletal muscle mass (SMM) from baseline (T0) to radiotherapy fraction 20 (T1), measured by multi-frequency bioelectrical impedance analysis (BIA).
SMM is expressed in kilograms (kg).
|
Baseline and fraction 20 (approximately 4 weeks after baseline)
|
|
Change in Body Fat Percentage
Délai: Baseline and fraction 20 (approximately 4 weeks after baseline).
|
Change in body fat percentage (BFP) from baseline (T0) to radiotherapy fraction 20 (T1), measured by multi-frequency bioelectrical impedance analysis (BIA).
BFP is expressed as a percentage (%).
|
Baseline and fraction 20 (approximately 4 weeks after baseline).
|
|
Change in Phase Angle
Délai: Baseline and fraction 20 (approximately 4 weeks after baseline)
|
Change in phase angle (PhA) from baseline (T0) to radiotherapy fraction 20 (T1), measured by multi-frequency bioelectrical impedance analysis (BIA).
PhA is expressed in degrees (°).
|
Baseline and fraction 20 (approximately 4 weeks after baseline)
|
|
Change in Fat-Free Mass
Délai: Baseline and fraction 20 (approximately 4 weeks after baseline)
|
Change in fat-free mass (FFM) from baseline (T0) to radiotherapy fraction 20 (T1), measured by multi-frequency bioelectrical impedance analysis (BIA).
FFM is expressed in kilograms (kg).
|
Baseline and fraction 20 (approximately 4 weeks after baseline)
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Chaoxing Liu, Dr, Shijiazhuang People's Hospital
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.
- Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.
- Kecojevic A, Ranken R, Ecker DJ, Massire C, Sampath R, Blyn LB, Hsieh YH, Rothman RE, Gaydos CA. Rapid PCR/ESI-MS-based molecular genotyping of Staphylococcus aureus from nasal swabs of emergency department patients. BMC Infect Dis. 2014 Jan 9;14:16. doi: 10.1186/1471-2334-14-16.
- Polack S, Adams M, O'banion D, Baltussen M, Asante S, Kerac M, Gladstone M, Zuurmond M. Children with cerebral palsy in Ghana: malnutrition, feeding challenges, and caregiver quality of life. Dev Med Child Neurol. 2018 Sep;60(9):914-921. doi: 10.1111/dmcn.13797. Epub 2018 May 7.
- Dai X, Feng J, Chen Y, Huang S, Shi X, Liu X, Sun Y. Traditional Chinese Medicine in nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Chin Med. 2021 Aug 3;16(1):68. doi: 10.1186/s13020-021-00469-4.
- Dou S, Ding H, Jiang W, Li R, Qian Y, Wu S, Ling Y, Zhu G. Effect of oral supplements on the nutritional status of nasopharyngeal carcinoma patients undergoing concurrent chemotherapy: A randomized controlled Phase II trial. J Cancer Res Ther. 2020;16(7):1678-1685. doi: 10.4103/jcrt.JCRT_273_20.
- Kohli K, Corns R, Vinnakota K, Steiner P, Elith C, Schellenberg D, Kwan W, Karvat A. A bioimpedance analysis of head-and-neck cancer patients undergoing radiotherapy. Curr Oncol. 2018 Jun;25(3):e193-e199. doi: 10.3747/co.25.3920. Epub 2018 Jun 28.
- Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM; IMPROVE-CKD Trial Investigators. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). J Am Soc Nephrol. 2020 Nov;31(11):2653-2666. doi: 10.1681/ASN.2020040411. Epub 2020 Sep 11.
- Bas D, Atahan C, Tezcanli E. An analysis of phase angle and standard phase angle cut-off values and their association with survival in head and neck cancer patients undergoing radiotherapy. Clin Nutr. 2023 Aug;42(8):1445-1453. doi: 10.1016/j.clnu.2023.06.020. Epub 2023 Jul 6.
- Prior-Sanchez I, Herrera-Martinez AD, Zarco-Martin MT, Fernandez-Jimenez R, Gonzalo-Marin M, Munoz-Garach A, Vilchez-Lopez FJ, Cayon-Blanco M, Villarrubia-Pozo A, Munoz-Jimenez C, Zarco-Rodriguez FP, Rabat-Restrepo JM, Luengo-Perez LM, Boughanem H, Martinez-Ramirez MJ, Garcia-Almeida JM. Prognostic value of bioelectrical impedance analysis in head and neck cancer patients undergoing radiotherapy: a VALOR(R) study. Front Nutr. 2024 Feb 22;11:1335052. doi: 10.3389/fnut.2024.1335052. eCollection 2024.
- Chen J, Guo Y, Wang C, Lin S, Shao L, Lan L, Guo F. Univariate and multivariate analysis of the styrofoam fixation device on patient setup errors in radiotherapy. J Appl Clin Med Phys. 2025 Jul;26(7):e70181. doi: 10.1002/acm2.70181.
- Ruan J, Huang X, Wang T, Mai X, Lin C, Li F, Li Y, Chi F, Li B. Impact of belly board immobilization devices and body mass factor on setup displacement using daily cone-beam CT in rectal cancer radiotherapy. J Appl Clin Med Phys. 2025 Mar;26(3):e14573. doi: 10.1002/acm2.14573. Epub 2024 Nov 29.
- Baba AY, Ahmad A, Baba OY, Shahid M. Assessing Axis-specific Set-up Errors in Rectal Cancer Radiotherapy: A Prospective Cone-beam Computed Tomography-Based Study with Body Mass Index Correlation. J Med Phys. 2025 Oct-Dec;50(4):731-736. doi: 10.4103/jmp.jmp_123_25. Epub 2025 Dec 31.
- Mulla Z, Hashem R, AlMohamad A, Weber A, Habibullah H, Abdulmoula G, Mohiuddin MG, Ujaimi R. Effect of Body Mass Factors on Setup Displacement in Gynecologic Tumors and Subsequent Effect on PTV Margins. Adv Radiat Oncol. 2022 Oct 25;8(1):101108. doi: 10.1016/j.adro.2022.101108. eCollection 2023 Jan-Feb.
- Costin IC, Marcu LG. Impact of immobilization system angle, body mass index and breast size on breast radiotherapy accuracy using EPID-only setup. Heliyon. 2025 Jan 22;11(3):e42176. doi: 10.1016/j.heliyon.2025.e42176. eCollection 2025 Feb 15.
- Wan B, Huan FK, Ge YD, Zhao RA, Zheng YT, Liang M, Zhang YX, Zhang W, Hou L, Zhang Y, Wang HK. Influence of Site, Surgery, and BMI Binary Classification on Positioning Errors in Radiotherapy for Breast Cancer Patients: A Retrospective Study. Cancer Rep (Hoboken). 2025 Sep;8(9):e70343. doi: 10.1002/cnr2.70343.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 juillet 2026
Achèvement primaire (Estimé)
31 décembre 2026
Achèvement de l'étude (Estimé)
31 mars 2027
Dates d'inscription aux études
Première soumission
18 juin 2026
Première soumission répondant aux critères de contrôle qualité
23 juin 2026
Première publication (Réel)
30 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
30 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
23 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SJZPH-RO-2026-001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .